Pulmonary hypertension inadequate to the clinical condition or hypoxemia disproportionate to the PH severity? (RCD code: II-1B.2)
We present four cases of patients with a history of a pulmonary hypertension (PH), who had a component of lung disease disproportionate to the PH severity. Detailed evaluation revealed pulmonary arterial hypertension (PAH) and patients were qualified to the targeted pharmacotherapy, however the treatment did not bring the significant improvement of patients' functional status. During follow-up, we observed deterioration of the clinical symptoms, that were not reflected in a significant progression of the right ventricle dysfunction.
This article provides information regarding pathogenesis, clinical characteristics, diagnostic evaluation and treatment of patients with PAH and presents the basic knowledge of the contribution of lung disorders to the PH development. JRCD 2015; 2 (5): 150–155
Galiè N, Humbert M, Vachiery JL, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2015 pii: ehv317. [Epub ahead of print].
Badesch BD, Champion HC, Gomez-Sanchez MA et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S55–S56.
Chaouat A, Bugnet A, Kadaoui N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 189-194.
Stenmark K, Fagan K, Frid M. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res 2006; 99: 675-691.
Joppa P, Petrasova D, Stancak B, et al. Systemic inflammation in patients with COPD and pulmonary hypertension. Chest 2006; 130: 326-333.
Chaouat A, Savale L, Chouaid C, et al. Role for interleukin-6 in COPD-related pulmonary hypertension. Chest 2009; 136: 678-687.
Jasiewicz M, Knapp M, Waszkiewicz E, et al. Enhanced IL-6 trans-signaling in pulmonary arterial hypertension and its potential role in disease-related systemic damage. Cytokine. 2015 Jul 8. pii: S1043-4666(15)30010-7. doi: 10.1016/j.cyto.2015.06.018. [Epub ahead of print].
Wright J, Levy R, Churg A. Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment. Thorax 2005; 60: 605-609.
Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet. 1981; 1: 681–686.
Hasegawa J, Wagner K, Karp D, et al. Altered pulmonary vascular reactivity in mice with excessive erythrocytosis. Am J Respir Crit Care Med 2004; 169: 829-835.
Nomura S, Tandon N, Nakamura T, et al. High-shear-stressinduced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. Atherosclerosis 2001; 158: 277-287.
Zhu Z, Li H, Zhang B. Expression of endothelin-1 and constitutional nitric oxide synthase messenger RNA in saphenous vein endothelial cells exposed to arterial flow shear stress. Ann Thorac Surg 1997; 64: 1333-1338.
Barbera JA, Roger N, Roca J, et al. Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease. Lancet 1996; 347: 436–440.
Blanco I, Gimeno E, Munoz PA, et al. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med 2010; 181: 270-278.
Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981; 1: 681-686.
Weitzenblum E, Sautegeau A, Ehrhart M, et al. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1985; 131: 493–498.
Adnot S, Samoyeau R, Weitzenblum E. Treatment of pulmonary hypertension in patients with chronic obstructive pulmonary disease: position of vasodilators with special focus on urapidil. Blood Press Supplement 1995; 3: 47-57.
Peacock AJ, Murphy NF, McMurray JJV, et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007; 30: 104–109.
- There are currently no refbacks.